{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:05:09Z","timestamp":1784250309916,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102599","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:16:05Z","timestamp":1781738165000},"page":"102599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC)"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9965-8925","authenticated-orcid":false,"given":"Meghan E.","family":"Mahoney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-2292","authenticated-orcid":false,"given":"Di Maria","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nely","family":"D\u00edaz-Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4613-3680","authenticated-orcid":false,"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Zlotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2930-4206","authenticated-orcid":false,"given":"Nimira","family":"Alimohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102599_bib0001","unstructured":"GLOBOCAN 2022: bladder cancer 9th most common worldwide. World Bladder Cancer Patient Coalition. Accessed June 3, 2025. Available at: https:\/\/worldbladdercancer.org\/news_events\/globocan-2022-bladder-cancer-is-the-9th-most-commonly-diagnosed-worldwide\/."},{"issue":"9","key":"10.1016\/j.clgc.2026.102599_bib0002","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2026.102599_bib0003","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102599_bib0004","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102599_bib0005","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"The advanced bladder cancer (ABC) meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","author":"Abol-Enein","year":"2003","journal-title":"The Lancet"},{"key":"10.1016\/j.clgc.2026.102599_bib0006","doi-asserted-by":"crossref","unstructured":"Desai A, Bouknight L, Reed T, et al. Factors influencing patient decision-making in the treatment of muscle-invasive bladder cancer. Bladder Cancer. 10(2):145-155. doi:10.3233\/BLC-240002.","DOI":"10.3233\/BLC-240002"},{"issue":"1","key":"10.1016\/j.clgc.2026.102599_bib0007","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clgc.2018.09.021","article-title":"Neoadjuvant chemotherapy before bladder-sparing chemoradiotherapy in patients with nonmetastatic muscle-invasive bladder cancer","volume":"17","author":"Jiang","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102599_bib0008","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102599_bib0009","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024)","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.clgc.2026.102599_bib0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","article-title":"Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline endorsement","volume":"34","author":"Milowsky","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102599_bib0011","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.clgc.2026.102599_bib0012","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16_Suppl","key":"10.1016\/j.clgc.2026.102599_bib0013","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e16596","article-title":"Real-world treatment practices in patients with muscle invasive bladder cancer (MIBC) treated in Alberta, Canada","volume":"42","author":"Alimohamed","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102599_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.05.009","article-title":"Outcomes for muscle-invasive bladder cancer with radical cystectomy or trimodal therapy in US veterans","volume":"30","author":"Kumar","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.clgc.2026.102599_bib0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102599_bib0016","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","volume":"7","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"27","key":"10.1016\/j.clgc.2026.102599_bib0017","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102599_bib0018","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"19","key":"10.1016\/j.clgc.2026.102599_bib0019","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2026.102599_bib0020","article-title":"Split-dose cisplatin in patients with locally advanced or metastatic urothelial carcinoma: a systematic literature review and network meta-analysis","volume":"22","author":"O\u2019Dwyer","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102599_bib0021","article-title":"Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","author":"Gupta","year":"2025","journal-title":"Eur Urol"},{"issue":"0","key":"10.1016\/j.clgc.2026.102599_bib0022","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"0","author":"Geynisman","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5_suppl","key":"10.1016\/j.clgc.2026.102599_bib0023","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.2025.43.5_suppl.815","article-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","volume":"43","author":"Ghatalia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102599_bib0024","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.clgc.2026.102599_bib0025","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5489\/cuaj.6459","article-title":"Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer","volume":"14","author":"Ajib","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2026.102599_bib0027","doi-asserted-by":"crossref","first-page":"S1557","DOI":"10.1016\/j.annonc.2023.10.347","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102599_bib0026","first-page":"486","article-title":"Perioperative enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer","volume":"395","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"7_suppl","key":"10.1016\/j.clgc.2026.102599_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102599_bib0028","unstructured":"Astellas Pharma Global Development, Inc. An open-label, single-arm, phase 2 study to evaluate enfortumab vedotin plus pembrolizumab for bladder preservation in participants with muscle-invasive bladder cancer (EV-209). 2026. Accessed June 7, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07475806."},{"key":"10.1016\/j.clgc.2026.102599_bib0029","unstructured":"Astellas pharma global development, inc. A phase 3, open-label, randomized study to evaluate enfortumab vedotin in combination with pembrolizumab in adult participants with muscle-invasive bladder cancer who are ineligible for or have elected not to undergo cystectomy. 2026. Accessed June 7, 2026. Available at: https:\/\/clinicaltrials.gov\/study\/NCT07566156."},{"issue":"7","key":"10.1016\/j.clgc.2026.102599_bib0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol Lond Engl"},{"issue":"8_Supplement_2","key":"10.1016\/j.clgc.2026.102599_bib0031","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT101","article-title":"Abstract CT101: ctDNA-guided immunotherapy following cystectomy in patients with urothelial carcinoma: preliminary results from the TOMBOLA Trial","volume":"85","author":"Dyrskj\u00f8t","year":"2025","journal-title":"Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:34:44Z","timestamp":1784248484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1558767326000996"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102599","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102599"}}